Quick Takeaways
- Bihua Chen has 5 issuer positions tracked on this page.
- Estimated disclosed ownership value: $238,003,038.
- Recent insider filing activity is available below.
- Info
- Portfolio
- Significant Ownership
- Insider Ownership
Insider Trading & Ownership of Bihua Chen
- Location
- Boston, MA
- Summary
- The estimated net worth of Bihua Chen is at least $238,003,038 dollars as of 28 Jan 2026. Bihua Chen is the Director, 10%+ Owner of BridgeBio Oncology Therapeutics, Inc. and owns shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) stock worth about $191.61M. Bihua Chen is the Director of Erasca, Inc. and owns shares of Erasca, Inc. (ERAS) stock worth about $17.19M. Bihua Chen is the Former 10% Owner of MoonLake Immunotherapeutics and owns shares of MoonLake Immunotherapeutics (MLTX) stock worth about $13.88M. Bihua Chen is the Chairperson and CEO, Director, 10%+ Owner of Helix Acquisition Corp. III and owns shares of Helix Acquisition Corp. III (HLXC) stock worth about $8M. Bihua Chen is the Former Director of Biomea Fusion, Inc. and owns shares of Biomea Fusion, Inc. (BMEA) stock worth about $7.33M.
- Signature
- /s/ Bihua Chen, Name: Bihua Chen
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Bihua Chen and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: BridgeBio Oncology Therapeutics, Inc. ($191,610,255).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Bihua Chen
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| BBOT | BridgeBio Oncology Therapeutics, Inc. | Director, 10%+ Owner | $191,610,255 | 11 Aug 2025 | ||
| ERAS | Erasca, Inc. | Director | $17,187,655 | 22 Jun 2023 | ||
| MLTX | MoonLake Immunotherapeutics | Former 10% Owner | $13,879,444 | -$46,868,184 | -77% | 29 Sep 2025 |
| HLXC | Helix Acquisition Corp. III | Chairperson and CEO, Director, 10%+ Owner | $8,000,000 | 26 Jan 2026 | ||
| BMEA | Biomea Fusion, Inc. | Former Director | $7,325,684 | 01 Aug 2025 |
Insider Transactions Reported by Bihua Chen:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.